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Background: Numerous epidemiological studies have been conducted to explore the association between
the Lys939Gln polymorphism of Xeroderma pigmentosum group C (XPC) gene and urinary bladder cancer
susceptibility. However, the results remain inconclusive. In order to derive a more precise estimation of this
relationship, a large and update meta-analysis was performed in this study.
Methods: A comprehensive search was conducted through researching MEDLINE, EMBASE, PubMed, Web of
Science, China Biomedical Literature database (CBM) and China National Knowledge Infrastructure (CNKI) databases
before June 2013. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the
strength of the association.
Results: A total of 12 studies with 4828 cases and 4890 controls for evaluating the XPC Lys939Gln polymorphism
and urinary bladder cancer were included. Overall, there was significant associations between the XPC Lys939Gln
polymorphism and urinary bladder cancer risk were found for homozygous model (OR = 1.352, 95% CL = 1.088-1.681),
heterozygous model (OR = 1.354, 95% CL = 1.085-1.688), and allele comparison (OR = 1.109, 95% CL = 1.013-1.214). In
subgroup analysis by ethnicity and source of controls, there were still significant associations detected in some genetic
models.
Conclusion: Our meta-analysis suggested that the XPC Lys939Gln polymorphism contributed to the risk of urinary
bladder cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1001118393101798.
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Bladder cancer is one of the most frequently occurring
neoplasms in men. The established risk factors for bladder
cancer include cigarette smoking, occupational exposure
to certain chemical carcinogens such as aromatic amines
and uptake of drugs such as phenacetin and cyclophos-
phamide. These carcinogens can cause DNA damage,* Correspondence: kundou_km@163.com
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reproduction in any medium, provided the orintroducing bulky adducts, crosslinks and single or double
strand breaks [1]. Tobacco smoke and occupational expo-
sures are the major risk factors in Western countries,
whereas schistosoma hematobium infection is the major
etiologic factor in developing countries, particularly in
Africa and the Middle East [2]. Although many people are
exposed to the risk factors, only a fraction of exposed indi-
viduals will develop bladder cancer, suggesting an individ-
ual susceptibility to the effects of carcinogens.
The xeroderma pigmentosum complementation group
C (XPC) protein is involved in the recognition and initi-
ation of the global genome repair pathway of nucleotide. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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XPC-HR23B complex, which recognizes and binds to
damaged DNA [3]. XPC gene is located at chromosome
3p25 and contains 16 exons and 15 introns, which is one
of the eight core genes (XPA, XPB, XPC, XPD, XPE, XPF,
XPG and ERCC1) in the NER pathway. Polymorphisms in
XPC gene have been evaluated as risk factors in bladder
cancer in a number of epidemiological studies, however
the conclusions were controversial. Therefore, in the pre-
sent study, we performed this meta-analysis of all the pub-
lished studies on bladder cancer to draw a more precise
estimation of this association.
Methods
Literature search
A comprehensive search was conducted through re.
searching MEDLINE, EMBASE, PubMed, Web of Science,
China Biomedical Literature database (CBM) and China
National Knowledge Infrastructure (CNKI) databases be-
fore June 2013. Relevant publications were searched using
follow terms: “XPC”, “Xeroderma pigmentosum group
C”, “polymorphism”, “variant”, “bladder cancer”, “bladder
tumor”, “bladder carcinoma” and “bladder neoplasm”. We
evaluated all associated publications to retrieve the most
eligible literatures. The reference lists of reviews and re-
trieved articles were hand searched at the same time. We
did not include abstracts or unpublished reports. When
overlapping data of the same patient population were in-
cluded in more than one publication, only the most recent
or complete study was used in this meta-analysis.
Inclusion and exclusion criteria
Studies included in our meta-analysis had to meet the
following inclusion criteria: (1) evaluate the association
between XPC Lys939Gln polymorphism and bladder
cancer risk; (2) case–control designed studies; (3) suffi-
cient information to estimate odds ratios (ORs) and their
95% confidence intervals (CIs). Studies were excluded if
one of the following existed: (1) no control population;
and (2) duplicate of previous publication.
Data extraction
Information was carefully assessed and extracted from all
eligible publications according to the inclusion criteria by
two investigators independently. For conflicting evaluation,
an agreement was reached following discussion during a
consensus meeting with a third reviewer. The following in-
formation was collected from each study: first author's
name, year of publication, country of origin, ethnicity, con-
trol source (hospital-based or population-based), genotyp-
ing methods, and numbers of cases and controls with the
XPC different genotypes distribution. The stratification
analysis was conducted by ethnicity and control source.Statistical methods
Crude odds ratios (ORs) with their corresponding 95%
CIs were used to assess the strength of association be-
tween the XPC Lys939Gln polymorphism and bladder
cancer risk. The pooled ORs and 95% CIs were calculated
for Lys939Gln polymorphism using homozygous model
(Gln/Gln vs. Lys/Lys), heterozygous model (Lys/Gln vs.
Lys/Lys), recessive model [Gln/Gln vs. (Lys/Gln + Lys/
Lys)], dominant model [(Lys/Gln + Gln/Gln) vs. Lys/Lys],
as well as allele comparison model (Gln vs. Lys). Pooled
OR estimate of each study was calculated by both
the fixed effects model (the Mantel–Haenszel method)
[4] and the random effects model (the DerSimonian and
Laird methods) [5]. The fixed-effects model would be
adopted when the studies were found to be homoge-
neous (with P > 0.10 for the Q test). Otherwise, the
random-effects model would be applied. Heterogeneity
between studies was evaluated by Chi square-based Q-
test [6]. Heterogeneity was considered statistically sig-
nificant if P < 0.10. Heterogeneity was quantified using
the I2 metric, which was independent of the number of
studies in the meta-analysis (I2 < 25% no heterogeneity,
I2 = 25–50% moderate heterogeneity, and I2 > 50% large
or extreme heterogeneity). Subgroup analyses were
performed by ethnicity and source of control to explore
the reasons of heterogeneity. The funnel plot was gener-
ated to examine the potential publication bias by using
the standard error of log (OR) of each investigation plot-
ted against its log (OR), and the asymmetry of funnel
plot was assessed by the method of Egger’s linear regres-
sion test [7]. Sensitivity analyses were performed to as-
sess the stability of the results. All statistical tests were
performed with Stata (Version 12.0, Stata Corporation,
College Station, TX), using two-sided P-values.
Results
Study characteristics
A total of 71 potentially relevant publications were identi-
fied from the databases listed above. After screening the ti-
tles or abstracts, 59 publications were excluded because of
duplicate data, case reports, or reviews, or non-relevance
research. All studies included in the present meta-analysis
used a case–control design. Finally, 12 studies were identi-
fied for eligibility and were included in our meta-analysis,
with a total of 4,828 cancer cases and 4,890 controls
[8-19] (Table 1). All patients in cases groups were histo-
logically or pathologically confirmed, and controls were
mainly matched by age, sex and ethnicity. The genotype
distribution of the Lys939Gln polymorphism was in com-
pliance with HWE in the controls of all studies.
Meta-analysis results
The overall results indicated that there were significant
associations between all three studied XPC Lys939Gln
Table 1 Main characteristics of these studies on the associations between XPC Lys939Gln polymorphism and bladder
cancer risk





Sanyal et al. 2004 Sweden Caucasian PB PCR-RFLP 309 246 0.294
Sak et al. 2005 England Caucasian HB TaqMan 532 561 0.191
Garcia-Closas et al. 2006 Spain Caucasian HB TaqMan 1137 1138 0.470
Wu et al. 2006 USA Caucasian HB TaqMan 606 596 0.744
Zhu et al. 2007 USA Caucasian HB Taqman 550 554 0.668
Fontana et al. 2008 French Caucasian HB TaqMan 51 45 0.456
de Verdier et al. 2010 Sweden Caucasian PB PCR-RFLP 305 328 0.147
Gangwar et al. 2010 India Asian HB PCR-RFLP 208 245 0.054
Rouissi et al.1 2011 Tunisia African HB PCR-RFLP 193 193 0.537
Rouissi et al.2 2011 Tunisia African HB PCR-RFLP 125 125 0.449
Mittal et al. 2012 India Asian PB PCR-RFLP 212 250 0.073
Liu et al. 2012 China Asian HB PCR-RFLP 600 609 0.824
PB Population-Based Study, HB Hospital-Based Study, PHWE P value of Hardy–Weinberg equilibrium. PCR-RFLP Polymorphism Chain Reaction- Restriction Fragment
Length Polymorphism. 1,2 Different studies.
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(Table 2). Overall, there is statistically significant associ-
ation was found between XPC Lys939Gln polymorphism
and the bladder cancer risk in homozygous model (OR =
1.39, 95% CI = 1.08-1.79) (Figure 1), heterozygous model
(Gln/Gln vs Gln/Lys: OR = 1.42, 95% CI = 1.11-1.83)Table 2 Main results of pooled odds ratios (ORs) with confide
Variables No. of studies
OR (95% CI) Ph P
Gln/Gln vs Lys/Lys
Total 9 1.352 (1.088 1.681) 0.000 0.00 1
Ethnicity
Caucasian 3 1.240 (0.927 1.658) 0.002 0.148 1
African 3 1.758 (1.097 2.819) 0.373 0.019 1
Asian 2 1.476 (1.110 1.962) 0.554 0.007 1
Source of controls
HB 5 1.225 (0.967 1.551) 0.009 0.093 1
PB 3 1.854 (1.338 2.569) 0.958 0.000 1
Variables No. of studies
OR (95% CI) Ph P
Lys/Lys vs Gln/Gln + Gln/Lys
(dominant model)
Total 9 0.945 (0.867 1.029) 0.397 0.194 1
Ethnicity
Caucasian 3 0.940 (0.814 1.085) 0.086 0.397 1
African 3 0.890 (0.649 1.220) 0.948 0.468 1
Asian 2 0.954 (0.803 1.133) 0.846 0.590 1
Source of controls
HB 5 0.962 (0.865 1.070) 0.264 0.480 1
PB 3 0.874 (0.718 1.065) 0.655 0.183 1
OR Odds Ratio, CL Confidence Interval, Ph P value of heterogeneity.(Figure 2), and allele comparison model (OR = 1.12,
95% CI = 1.003-1.24) (Figure 3), but not in other models
(Table 2). In the subgroup analysis by ethnicity, statisti-
cally significant associations were observed in African
populations for homozygous model (OR = 1.758, 95% CI =
1.097-2.819), and recessive model (OR = 1.781, 95% CI =nce interval (CI) in the meta-analysis
OR (95% CI) Ph P OR (95% CI) Ph P
Gln/Gln vs Gln/Lys Gln/Lys vs Lys/Lys
.354 (1.085 1.688) 0.001 0.007 1.017 (0.932 1.109) 0.592 0.712
.184 (0.913 1.536) 0.006 0.203 1.041 (0.938 1.155) 0.278 0.448
.800 (0.969 3.342) 0.196 0.063 0.955 (0.680 1.341) 0.575 0.791
.586 (1.105 2.276) 0.256 0.012 0.962 (0.802 1.154) 0.655 0.677
.233 (0.969 1.570) 0.88 0.088 1.017 (0.924 1.120) 0.382 0.728
.806 (1.310 2.491) 0.896 0.000 1.013 (0.823 1.247) 0.678 0.900
OR (95% CI) Ph P OR (95% CI) Ph P
Gln/Gln vs Gln/Lys + Lys/Lys
(recessive model) Gln allele vs Lys allele
.362 (1.099 1.688) 0.18 0.18 1.109 (1.013 1.214) 0.019 0.024
.219 (0.934 1.591) 0.002 0.145 1.097 (0.960 1.254) 0.003 0.175
.781 (1.057 3.002) 0.241 0.030 1.258 (1.001 1.579) 0.546 0.049
.489 (1.130 1.962) 0.357 0.005 1.123 (0.989 1.275) 0.996 0.073
.239 (0.982 1.563) 0.003 0.071 1.078 (0.971 1.197) 0.021 0.160
.824 (1.343 2.477) 0.956 0.000 1.233 (1.067 1.423) 0.749 0CPA004
Figure 1 Forest plots for XPC Lys939Gln polymorphism and risk of bladder cancer in overall populations (homozygous model for Gln/
Gln vs Lys/Lys).
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http://www.diagnosticpathology.org/content/8/1/1121.057-3.002). Similarly, statistically significant associations
were observed in Asian populations for homozygous
model (OR = 1.476, 95% CI = 1.110-1.962), heterozygous
model (Gln/Gln vs Gln/Lys: OR = 1.586, 95% CI = 1.105-
2.276), and recessive model (OR = 1.489, 95% CI = 1.130-
1.962). However, no statistical associations were found in
Caucasian populations for other genetic models (Table 2).
In population-based populations, statistically significantFigure 2 Forest plots for XPC Lys939Gln polymorphism and risk of bl
Gln vs Gln/Lys).associations were found for homozygous model (OR =
1.854, 95% CI = 1.338-2.569), heterozygous model (Gln/
Gln vs Gln/Lys: OR = 1.806, 95% CI = 1.310 -2.491), reces-
sive model (OR = 1.489, 95% CI = 1.130-1.962) and allele
comparison model (OR = 1.233, 95% CI = 1.067-1.423),
while there are no statistical associations were found in
hospital-based populations for all kinds of comparison
models.adder cancer in overall populations (heterozygous model for Gln/
Figure 3 Forest plots for XPC Lys939Gln polymorphism and risk of bladder cancer in overall populations (allele comparison for
Gln allele vs. Lys allele).
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Substantial heterogeneities were observed in the over-
all analysis evaluating the association between XPC
Lys939Gln polymorphism and bladder cancer risk in
homozygous model (P = 0.000), heterozygous model
(Gln/Gln vs Gln/Lys: P = 0.007), and allele comparison
(P = 0.007), except for the heterozygous (Gln/Lys vsFigure 4 Begg’s funnel plot for assessing the publication bias under t
Lys allele).Lys/Lys: P = 0.348), dominant model (P = 0.397), and re-
cessive model (P = 0.18).
Sensitivity analyses
We next performed a leave-one-out sensitivity analysis
to determine whether a particular study or studies would
result in heterogeneity. It was found that one study [13]he allele contrast model (allele comparison for Gln allele vs.
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http://www.diagnosticpathology.org/content/8/1/112with small sample size, 51 cases and 45 controls, and obvi-
ous genotype frequency deviation may qualitatively change
the pooled ORs for Lys939Gln polymorphism. After this
study was dropped, the degree of heterogeneity dramatic-
ally decreased, without altering the overall estimates.
Publication bias
Begg’s funnel plot and Egger’s test were performed to as-
sess the publication bias. The shape of funnel plots did not
reveal any evidence of obvious asymmetry in all compari-
son models, and the results of Begg’s test did not show any
evidence of publication bias (Figure 4).
Discussion
It is well recognized that there is a range of individual sus-
ceptibility to the same kind of cancer even with identical
environmental exposure. Host factors, including polymor-
phisms of genes involved in carcinogenesis, may have
accounted for this difference. Therefore, genetic suscepti-
bility to cancer has been a research focus in scientific
community.
This meta-analysis, including 4,828 cancer cases and
4,890 controls from 12 published case–control studies,
explored the association between the XPC Lys939Gln
polymorphism and bladder cancer risk. Overall, we
found that there was evidence that the variant genotypes
of the XPC Lys939Gln were associated with a significant
increased overall risk of bladder cancer. In the subgroup
analysis based on ethnicities, significant associations
were found between both African and Asian populations
for some genetic models, suggesting that XPD Lys939Gln
polymorphism play similar roles in populations with dif-
ferent genetic backgrounds and living environment. Sim-
ultaneously, our results also showed that significantly
increased bladder cancer risk in homozygous, heterozy-
gous, recessive and allele comparison models were noted
in the population-based studies but not in hospital-based
studies.
There are some limitations should be acknowledged in
this meta-analysis. Firstly, bladder cancer is a multi-factorial
disease that results from complex interactions between
many genetic and environmental factors. It suggests that
there will not be single gene or single environmental factor
that has large effects on bladder cancer susceptibility. Sec-
ondly, in the subgroup analyses by ethnicity and source of
controls, the number of subjects was relatively small, not
having enough statistical power to explore the real associ-
ation. Thirdly, the controls were not uniformly defined. Al-
though most of the controls were selected mainly from
healthy populations, some had respiratory disease. There-
fore, non-differential mis-classification bias was possible be-
cause these studies may have included the control groups
who had different risks of developing bladder cancer.
Fourth, our meta-analysis is similarly with other works[20-22], while a more precise analysis should be conducted
if individual data were available, which would allow for the
adjustment by other covariates including age, sex, family
history, environmental factors and lifestyle. Furthermore,
other pathological type of urinary bladder cancer should be
considered [23-25], which may be the source of publication.
In addition, as in most meta-analyses, publication bias must
be considered because only published studies were included
in the meta-analysis.
Despite some limitations listed above, our meta-analysis
had several advantages. First, sufficient number of cases
and controls were pooled from different studies, which
significantly increased the statistical power of the analysis.
Second, no publication biases were detected, indicating
that there is no bias among the pooled results.
Conclusion
In conclusion, this meta-analysis indicates that XPC
Lys939Gln polymorphism may be contributed to the devel-
opment of bladder cancer risk. However, a study with the
larger sample size is needed to further evaluated gene-
environment interaction on XPC Lys939Gln polymorphism
and bladder cancer risk.
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